Tumor necrosis factor alpha in ulcerative colitis and diverticular disease associated colitis

Cesare Hassan, A Zullo, V De Francesco, Sma Campo, S Morini, C Panella, E. Ierardi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

Conventional treatment of moderate-severe ulcerative colitis (UC) has resulted in only a limited therapeutic benefit. Advancing knowledge of UC pathogenesis and recent advances in biotechnology have led to the development of biological agents that selectively target individual inflammatory pathways. In particular, the role of tumor necrosis factor alpha (TNF-alpha) in UC pathogenesis has been clarified by serological and immunohistochemical studies in humans and by experimental models. Clinical efficacy of anti-TNF-alpha therapy with infliximab has been assessed in two large controlled trials, showing a good compromise between therapeutic gain and safety. The aim of this review is to provide an insight into the role of TNF-alpha and anti-TNF-alpha therapy in patients with UC and diverticular disease associated colitis.
Lingua originaleEnglish
pagine (da-a)187-194
Numero di pagine8
RivistaENDOCRINE, METABOLIC & IMMUNE DISORDERS DRUG TARGETS
Volume7
Stato di pubblicazionePubblicato - 2007
Pubblicato esternamenteYes

Keywords

  • Animals
  • Colitis
  • Colitis, Ulcerative
  • Diverticulum
  • Humans
  • Tumor Necrosis Factor-alpha

Fingerprint

Entra nei temi di ricerca di 'Tumor necrosis factor alpha in ulcerative colitis and diverticular disease associated colitis'. Insieme formano una fingerprint unica.

Cita questo